End-of-day quote
Other stock markets
|
||
- GBX | - |
10:07pm | Delaware judge lets more than 70,000 Zantac lawsuits go forward | RE |
09:35am | GSK Regarding Ruling By Delaware State Court On Zantac Litigation Will Immediately Seek Appeal | RE |
Sales 2024 * | 31.64B 40.31B 54.93B | Sales 2025 * | 33.59B 42.8B 58.32B | Capitalization | 72.04B 91.78B 125B |
---|---|---|---|---|---|
Net income 2024 * | 5.56B 7.08B 9.65B | Net income 2025 * | 6.5B 8.29B 11.29B | EV / Sales 2024 * | 2.67 x |
Net Debt 2024 * | 12.39B 15.79B 21.52B | Net Debt 2025 * | 8.95B 11.4B 15.54B | EV / Sales 2025 * | 2.41 x |
P/E ratio 2024 * |
12.8
x | P/E ratio 2025 * |
11.1
x | Employees | - |
Yield 2024 * |
3.45% | Yield 2025 * |
3.57% | Free-Float | 94.54% |
Latest transcript on GlaxoSmithKline plc
Managers | Title | Age | Since |
---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 55 | 10-04-30 |
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
James Ford
CMP | Compliance Officer | - | 95-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
Jonathan Symonds
CHM | Chairman | 66 | 19-08-31 |
Hal Barron
BRD | Director/Board Member | 62 | 17-12-31 |
1st Jan change | Capi. | |
---|---|---|
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
-5.52% | 206B | |
+6.17% | 164B | |
-0.45% | 162B |